Donghao Shang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4206899/publications.pdf

Version: 2024-02-01

21 papers	224 citations	1040018 9 h-index	996954 15 g-index
21 all docs	21 docs citations	21 times ranked	405 citing authors

#	Article	IF	Citations
1	TGFBI-promoted Adhesion, Migration and Invasion of Human Renal Cell Carcinoma Depends on Inactivation of von Hippel-Lindau Tumor Suppressor. Urology, 2012, 79, 966.e1-966.e7.	1.0	49
2	Synergy of 5-aza-2â€²-deoxycytidine (DAC) and paclitaxel in both androgen-dependent and -independent prostate cancer cell lines. Cancer Letters, 2009, 278, 82-87.	7.2	25
3	FOXJ1 promotes bladder cancer cell growth and regulates Warburg effect. Biochemical and Biophysical Research Communications, 2018, 495, 988-994.	2.1	21
4	5-Aza-2â€²-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel by decreasing LEF1/phospho-Î²-catenin expression. Cancer Letters, 2011, 311, 230-236.	7.2	20
5	Interferon-Î± Induces G1 Cell-Cycle Arrest in Renal Cell Carcinoma Cells Via Activation of Jak-Stat Signaling. Cancer Investigation, 2011, 29, 347-352.	1.3	15
6	New mechanistic insights of clear cell renal cell carcinoma from integrated miRNA and mRNA expression profiling studies. Biomedicine and Pharmacotherapy, 2019, 111, 821-834.	5.6	13
7	Transforming growth factor-Î²1 enhances proliferative and metastatic potential by up-regulating lymphoid enhancer-binding factor 1/integrin Î±MÎ²2 in human renal cell carcinoma. Molecular and Cellular Biochemistry, 2020, 465, 165-174.	3.1	13
8	Profiling of mRNA and long non-coding RNA of urothelial cancer in recipients after renal transplantation. Tumor Biology, 2016, 37, 12673-12684.	1.8	11
9	Epirubicin suppresses proliferative and metastatic potential by downregulating transforming growth factorâ€Î²â€induced expression in urothelial carcinoma. Cancer Science, 2018, 109, 980-987.	3.9	10
10	Peroxisome proliferator-activated receptor Î³ (PPARÎ³) suppresses the proliferation and metastasis of patients with urothelial carcinoma after renal transplantation by inhibiting LEF1/Î²-catenin signaling. Bioengineered, 2020, 11, 1350-1367.	3.2	10
11	Protein tyrosine phosphatase Î¶ enhances proliferation by increasing Î²-catenin nuclear expression in VHL-inactive human renal cell carcinoma cells. World Journal of Urology, 2013, 31, 1547-1554.	2.2	7
12	ZSCAN16 promotes proliferation, migration and invasion of bladder cancer via regulating NF-kB, AKT, mTOR, P38 and other genes. Biomedicine and Pharmacotherapy, 2020, 126, 110066.	5.6	7
13	Diagnostic value comparison of CellDetect, fluorescent in situ hybridization (FISH), and cytology in urothelial carcinoma. Cancer Cell International, 2021, 21, 465.	4.1	7
14	Expression and Proliferation-Promoting Role of Lymphoid Enhancer-Binding Factor 1 in Human Clear Cell Renal Carcinoma. Cancer Investigation, 2014, 32, 368-374.	1.3	5
15	HengliÂ® Chinese Botulinum Toxin Type A for Treatment of Patients With Overactive Bladder: A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial. Frontiers in Pharmacology, 2022, 13, 840695.	3.5	3
16	Interferon-Î± enhances the susceptibility of renal cell carcinoma to rapamycin by suppressing mTOR activity. Experimental and Therapeutic Medicine, 2014, 8, 267-273.	1.8	2
17	Exosome-Transmitted miR-128 Targets CCL18 to Inhibit the Proliferation and Metastasis of Urothelial Carcinoma. Frontiers in Molecular Biosciences, 2021, 8, 760748.	3.5	2
18	VHL-TGFBI signaling is involved in the synergy between 5-aza-2'-deoxycytidine and paclitaxel against human renal cell carcinoma. Journal of B U on, 2017, 22, 500-507.	0.4	2

#	Article	IF	Citations
19	The link between FOXJ1 expression level in bladder carcinoma and tumor recurrence. Oncology Letters, 2017, 15, 1483-1486.	1.8	1
20	Synergistic inhibitory effects of 5-aza-2â€²-deoxycytidine and cisplatin on urothelial carcinoma growth via suppression of TGFBI-MAPK signaling pathways. Biochemistry and Cell Biology, 2022, 100, 115-124.	2.0	1
21	VHL-TGFBI signaling is involved in the synergy between 5-aza-2'-deoxycytidine and paclitaxel against human renal cell carcinoma. Journal of B U on, 2017, 22, 1038-1045.	0.4	0